Roche shares surge as a dou­ble-shot win in I/O and he­mo­phil­ia rais­es block­buster ex­pec­ta­tions

Roche has scored a win with one of the key im­muno/on­col­o­gy tri­als of the year, post­ing sig­nif­i­cant top-line gains for pro­gres­sion-free sur­vival and risk of death for a seg­ment of lung can­cer pa­tients get­ting first-line treat­ment with a triple com­bo of its check­point ther­a­py Tecen­triq, Avastin and chemo. And it swept a dou­ble head­er ear­ly this morn­ing with their re­port of an­oth­er suc­cess­ful late-stage study for its new­ly ap­proved he­mo­phil­ia A drug Hem­li­bra, fur­ther set­ting the stage for a painful show­down with mar­ket leader Shire.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA